The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

A 2022 analysis by the Reagan-Udall Foundation noted that the FDA had "struggled to function as a regulator in part due to some of its policy choices," including the "scope of the product review regulations," which "have been difficult for both stakeholders and [the FDA] to apply in practice."